Uses and Compositions for Treatment of Psoriasis

Abstract

The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject.

What is claimed: 
     
         1 . A method of improving a DLQI score of a subject having psoriasis from a large/extremely large score to a no or small impact score comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject, such that the DLQI score improves from the large/extremely large score to the no or small impact score. 
     
     
         2 . A method of decreasing a Physician's Global Assessment (PGA) score of a subject having psoriasis by at least about 2 points comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject, such that the PGA score is decreased by at least about 2 points. 
     
     
         3 . A method of treating a subtherapeutic response to an original dose of a human TNFα antibody, or an antigen-binding portion thereof, in a subject having psoriasis comprising administering the human TNFα antibody, or antigen binding portion thereof, to the subject at an increased dosing rate which is about twice as frequent as the original dosing rate. 
     
     
         4 . The method of  claim 3 , wherein the increased dosing rate is weekly. 
     
     
         5 . The method of  claim 3 , wherein the subtherapeutic response is defined as less than a PASI 50 response determined between baseline (week 0) and a time period following baseline. 
     
     
         6 . The method of  claim 5 , wherein the response is determined between baseline and at least about 24 weeks following baseline. 
     
     
         7 . A method for determining the efficacy of a human TNFα antibody, or an antigen-binding portion thereof, for improving the functional limitations of a subject having psoriasis comprising
 determining an improvement in a DLQI score from a patient population who was administered the human TNFα antibody, or antigen-binding portion thereof, 
 wherein a DLQI score of no or small impact in at least about 67% of the patient population indicates that the human TNFα antibody, or antigen-binding portion thereof, is an effective human TNFα antibody, or antigen-binding portion thereof, for improving the functional limitations of a subject having psoriasis. 
 
     
     
         8 . The method of  claim 7 , wherein the subject has a baseline PASI score greater than or equal to 10 and a baseline DLQI score greater than about 10. 
     
     
         9 . The method of  claim 1 , wherein the human TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         10 . The method of  claim 2 , wherein the human TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         11 . The method of  claim 3 , wherein the human TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         12 . The method of  claim 7 , wherein the human TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         13 . The method of  claim 1 , wherein the human TNFα antibody, or antigen-binding portion thereof, is adalimumab. 
     
     
         14 . The method of  claim 2 , wherein the human TNFα antibody, or antigen-binding portion thereof, is adalimumab. 
     
     
         15 . The method of  claim 3 , wherein the human TNFα antibody, or antigen-binding portion thereof, is adalimumab. 
     
     
         16 . The method of  claim 7 , wherein the human TNFα antibody, or antigen-binding portion thereof, is adalimumab. 
     
     
         17 . The method of  claim 7 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population on a biweekly dosing regimen. 
     
     
         18 . The method of  claim 7 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population in a dose of about 40 mg. 
     
     
         19 . The method of  claim 7 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population via subcutaneous administration. 
     
     
         20 . The method of  claim 1 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population on a biweekly dosing regimen. 
     
     
         21 . The method of  claim 2 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population on a biweekly dosing regimen. 
     
     
         22 . The method of  claim 3 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population on a biweekly dosing regimen. 
     
     
         23 . The method of  claim 1 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population in a dose of about 40 mg. 
     
     
         24 . The method of  claim 2 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population in a dose of about 40 mg. 
     
     
         25 . The method of  claim 3 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population in a dose of about 40 mg. 
     
     
         26 . The method of  claim 1 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population via subcutaneous administration. 
     
     
         27 . The method of  claim 2 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population via subcutaneous administration. 
     
     
         28 . The method of  claim 3 , wherein the human TNFα antibody, or antigen-binding portion thereof, was administered to the patient population via subcutaneous administration.